Immunotherapy: Open Access
Open Access

Immunologic Adjuvant: Overview and Types

Feng Yang^{* *}Correspondence: Feng Yang, Department of Gastrointestinal Surgery, Zaozhuang Municipal Hospital, Zaozhuang City, China, Email:

Author info »

About the Study

An adjuvant is a chemical used in immunology to boost or alter the immune response to a vaccine. The word "adjuvant" is derived from the Latin word adiuvare, which means to assist or help. When used in conjunction with certain vaccination antigens, an immunologic adjuvant is described as any chemical that works to accelerate, extend, or augment antigen-specific immune responses. Significant differences in the efficacy of several batches of the same vaccine were properly considered to be caused by contamination of the reaction vessels in the early days of vaccine production [1]. However, it was subsequently discovered that more thorough cleaning actually reduced the vaccine's potency, and that some impurities actually boosted the immunological response. Many recognised adjuvants, such as aluminium salts, oils, and virosomes, are widely used.

Types

Inorganic adjuvants: Many adjuvants, some organic and some inorganic, have the potential to improve immunogenicity. Alum was the first aluminium salt used for this purpose, but aluminium hydroxide and aluminium phosphate have nearly completely superseded it in commercial vaccinations. In human immunizations, aluminium salts are the most often used adjuvants. In 1926, their adjuvant activity was discovered. Although the exact mechanism of aluminium salts is unknown, some insights have been acquired. Previously, it was considered that they work as delivery systems by forming depots that store antigens at the injection site, allowing for a gradual release of antigens that continues to excite the immune system [2]. Surgical excision of these depots, on the other hand, had no effect on the size of the IgG1 response, according to research. Interleukin 1 beta, an immunological signal that increases antibody formation, can be secreted by dendritic cells and other immune cells when exposed to alum. Alum attaches to the cell's plasma membrane, causing lipids to rearrange. Dendritic cells are triggered into action, picking up the antigen and racing to lymph nodes, where they cling to a helper T cell, presumably inducing an immunological response. A second mechanism relies on alum destroying immune cells at the injection site, however scientists aren't clear how this happens. It's been suggested that dying cells release DNA that acts as an immunological warning.

Organic adjuvants: Freund's complete adjuvant, discovered in 1930, is a solution of inactivated Mycobacterium tuberculosis in mineral oil. It is not suitable for human consumption. Freund's incomplete adjuvant is a variant of the bacteria-free adjuvant that is merely oil in water. It assists immunizations in releasing antigens for a longer period of time [3]. Despite the negative side effects, clinical trials have been conducted. Squalene is an organic chemical found in nature that is utilised in human and animal vaccinations. Squalene is a carbon and hydrogen-based oil generated by plants and found in a variety of foods. Human sebum contains squalene, which is produced by the liver as a precursor to cholesterol.

Conclusion

Adjuvants are commonly employed in immunology to modify or augment the effects of a vaccination by activating the immune system to respond more strongly to the vaccine, resulting in improved immunity to a certain disease. Endocytosed nucleic acids such as double-stranded RNA, double-stranded RNA, single-stranded DNA, and unmethylated CpG dinucleotidecontaining adjuvants accomplish this task by mimicking specific sets of evolutionarily conserved molecules known as pathogenassociated molecular patterns, which include liposomes, lipopolysaccharide, molecular cages for antigens and components of bacterial cell. Because immune systems have evolved to recognise these specific antigenic moieties, adding an adjuvant to a vaccine can significantly boost the innate immune response to the antigen by enhancing the activity of dendritic cells, lymphocytes, and macrophages, simulating a genuine infection.

References

1. Mohammad IS, Teng C, Chaurasiya B, Yin L, Wu C, He W. Drug-delivering-drug approach-based codelivery of paclitaxel and disulfiram for treating multidrug-resistant cancer. Int J Pharm 2019; 557:304-13.
2. Zhu Y, Yu X, Thamphiwatana SD, Zheng Y, Pang Z. Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy. Acta Pharmaceutica Sinica B. 2020 Aug 27.
3. Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019 Mar; 18(3):175-96.